MYC is not overexpressed in a case of chronic myelomonocytic leukemia with MYCcontaining double minutes TO THE EDITOR Double minutes (dmin) consist of circular acentric chromatin and are a cytogenetic manifestation of gene amplification, presumably providing the cell with a large number of copies of the target oncogene and resulting in growth advantage. They have been reported in a wide variety of neoplastic disorders, being particularly common in neuroblastomas and brain tumors. 1 In hematologic malignancies, however, dmin are found in less than 1% of larger series of acute myeloid leukemias (AML), myelodysplastic syndromes (MDS), chronic myeloproliferative disorders, chronic myeloid leukemias, and acute lymphoblastic leukemias. 1 In these diseases, dmin appear to be more frequent in myeloid malignancies, especially AML, 1 and may be associated with a poor prognosis. 2, 3 Most cases display additional chromosomal aberrations; the few cases reported to date with dmin as a sole abnormality have, with one exception, all been AML. 1 Molecular genetic investigations of dmin in hematologic malignancies have revealed that the vast majority contains amplified sequences derived from chromosome band 8q24, including the MYC oncogene, but dmin harboring MLL have also been reported as well as some with amplification of none of these genes. It has been suggested that the amplification of MYC in hematologic disorders with dmin results in an overexpression of this gene and that this would be the pathogenetically important outcome of the aberration. 2, 3 However, an expression analysis of MYC in dmin has only been performed on the leukemic cell line HL60; 4 no such studies of primary hematologic malignancies have been reported to date.
We here describe a chronic myelomonocytic leukemia (CMML) with dmin as the sole chromosomal aberration. In addition, we show, by fluorescence in situ hybridization (FISH) and Northern blot analyses, that MYC is amplified but not overexpressed, strongly suggesting that it is not the target gene.
A 77-year-old woman with atrial fibrillation, hypertension, and hypothyroidism was admitted to the hospital in December 2000 because of increasing fatigue. She had no previous history of malignancy or iatrogenic genotoxic exposure. At admission, the peripheral blood values were as follows: hemoglobin 93 g/l, platelets 100 Â 10 9 /l, and white blood cells (WBC) 60 Â 10 9 /l with monocytosis. The physical examination was unremarkable; there was no hepatosplenomegaly. Microscopy of a blood film showed massive neutrophilia with hypogranulation, occasional metamyelocytes and myelocytes, monocytosis (4.8 Â 10 9 /l), and nucleated erythrocytes (8/200 WBC). The bone marrow smears were hypercellular with expanded granulocytopoiesis. The myeloblast count was normal. Dysplastic features were limited to neutrophilic hypogranulation and the finding of a few megakaryocytes with multiple separate nuclei. A diagnosis of CMML of the myeloproliferative type was made. She was initially treated with hydroxyurea, later supplemented with cytosine arabinoside because of increasing proliferation. However, the patient's condition deteriorated gradually, and she succumbed to the disease in August 2001, 8 months after the diagnosis.
The karyotype by G-banding analysis was 46,XX,8-40dmin[12]/ 46,XX[13] at diagnosis, and no additional aberrations were detected with multicolor-FISH using whole chromosome painting (wcp) probes for combined binary ratio labeling-FISH.
5 FISH using a probe specific for MYC (Vysis Inc., USA) showed that this gene was present in all dmin, as well as in its normal locus at 8q24 ( Figure 1 ). However, a Northern blot analysis revealed that although MYC was slightly more expressed than in a normal bone marrow, the level of expression was markedly lower than in a CMML without dmin or trisomy 8 and than in two cell lines (Figure 2 ), indicating that the amplification had not caused overexpression of this gene.
Dmin as a sole chromosomal aberration is a rare finding in hematologic malignancies; only 13 cases have been reported to date, and of these, 12 were AML, mainly M2 variants in elderly patients. 1 It is noteworthy that the single non-AML described with dmin as an isolated change was a CMML. 6 The present case is thus the second CMML with dmin as the only chromosomal abnormality. The rapid clinical deterioration of our patient, who died after 8 months, agrees well with several previous reports stating that dmin in general, as well as MYC-containing dmin, is associated with a short survival. 2 However, this has been questioned recently by Bruckert et al, 3 who, in a review of 11 AML with dmin harboring MYC, concluded that dmin may not confer a poor prognosis unless associated with a complex karyotype. In line with this, the CMML patient reported by Sambani et al 6 survived more than 20 months. Furthermore, reviewing the 12 AML with dmin as a sole change 1 revealed survival times of more than 1 year in 7 of the 10 informative cases. Considering that the median age of these 10 AML patients was 73 years (range 64-79), dmin as the single abnormality cannot be claimed to be a poor prognostic sign.
In the present case, the FISH investigation with a probe covering MYC revealed signals for this gene in all dmin, as well as in its normal locus at 8q24 (Figure 1) . Surprisingly, the Northern blot analysis disclosed that MYC was less expressed than in the CMML without dmin (Figure 2 Correspondence not the true target of amplification, at least not in the present case, and that dmin derived from 8q24 may contain other genes with pathogenetic effects. Considering this unexpected result, it is remarkable that only one previous expression study regarding genes present in dmin in hematologic malignancies has been reported, 4 although the need for such investigations has been stressed. 7 The one study performed described, contrary to our finding, an overexpression of MYC in the dmin-containing HL60 leukemic cell line, but other sequences derived from 8q24 had even higher levels of expression, 4 supporting the possibility of other target genes. In addition, an increased level of MYC protein was not detected in the CMML case reported by Sambani et al. 6 However, in that study it was not confirmed that the dmin harbored the MYC gene.
Two previous studies of AML have reported the presence of a second amplified gene in dmin containing material from 8q24, 7, 8 namely PVT1, which is disrupted in some Burkitt's lymphomas with variant translocations.
1 Needless to say, other genes in this area may also be coamplified. In fact, Crossen et al 7 showed that the dmin amplicon in one AML case was at least 780 kb, a segment that could well contain several genes. Furthermore, analyses of solid tumors have shown that material from other chromosomes, even fusion genes, may be present in dmin. 1 Considering these studies, as well as our finding, it is apparent that more extensive mappings of dmin in hematologic malignancies are necessary. In conclusion, the present case emphasizes the need for expression studies before deciding that a particular amplified gene is essential in the leukemogenic process.
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From the paternally imprinted and maternally expressed H19 gene, an untranslated RNA is generated that exerts growth regulatory functions during embryogenesis and acts as a potential tumor suppressor in some types of cancer. It is a developmentally regulated gene and, thus, abundantly expressed in several fetal tissues, and repressed in most organs after birth. 1 It has been elucidated that the untranslated RNA retains a high potency of antiproliferative effects and acts directly as a tumor suppressor.
2 So far, no H19 protein could be identified. 2 Little is known about the role of H19 in normal and neoplastic hematopoiesis. In precursor cells of patients with polycythemia vera, a reduced expression of H19 could be demonstrated. 3 To assess the level of H19 in total bone marrow cells, we quantitatively focused on its expression in reactive lesions and chronic myeloproliferative disorders (CMPD). A total of 59 formalin-fixed, paraffin-embedded (FFPE) bone marrow trephines with histopathologically proven and clinically untreated CMPD (17 polycythemia vera (PV), 11 essential thrombocythemia (ET), 11 chronic myeloid leukemia (CML), 10 idiopathic myelofibrosis (IMF) in the cellular phase, 10 IMF with demonstrable fiber increase), 12 cases with chronic myelomonocytic leukemia (CMML), and 33 control cases (bone marrow biopsies with no evidence of a neoplastic disease) were retrieved from the Bone Marrow Registry, Institute of Pathology, Medizinische Hochschule Hannover. Total RNA was extracted using an optimized protocol for the extraction of RNA from FFPE archival tissues.
5 Total RNA (1 mg), pretreated with RNase-free DNase (RQ1, Promega, USA), was transcribed to the complementary DNA (cDNA) according to the manufacture's protocol using SuperScript II Rnase À Reverse Transcriptase (Invitrogen, Karlsruhe, Germany).
As a first step to assess a potential role of H19 in normal hematopoiesis and myeloproliferative diseases, we established the quantitative RNA expression in normal bone marrow cells. In both normal bone marrow cells and those from reactive states, a relatively constant level could be found without interindividual differences. Compared to the basal expression level in controls, bone marrow cells from CMPD expressed a significantly lower H19 level. PV, ET, and CML cases showed an up to six fold reduced H19 expression (Po0.0001), while IMF in the cellular and fibrotic phases expressed three-fold less H19 (P ¼ 0.001) compared to healthy controls. CMML exhibited a 20-fold lower H19 level than control cases (Po0.0001). When compared with each other, CMPD and CMML cases did not differ significantly with regard to H19 expression, (Figure 1) .
The function and role of H19 in normal and malignant hematopoiesis largely remains unknown. A recent study demonstrated a tight regulation of H19 expression in lineage commitment. The most intriguing data, although obtained in a small-scale study, were evidence of reduced H19 expression in precursor cells of A quantitative real-time RT-PCR assay was performed using an ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Primer and probes for the quantitative analysis of H19 RNA and the housekeeping gene b-glucuronidase (b-GUS) were H19 forward primer 5 0 -TGGTTGGAGTTGTGGAGACG; H19 reverse primer 5 0 -CACTTGCCAAGGTGGCTCA; and H19 probe 5 0 -CCTTGAGTCTCAGTACGAGTGTGCGTGAGT.
b-GUS forward primer 5 0 -CTCATTTGGAATTTTGCCGATT, b-GUS reverse primer 5 0 -AGTGAAGATCCCCTTTTTA, and b-GUS probe 5 0 -TGAACAGT-CACCGACGAGAGTGCTGG. The DDC T -method for quantification of H19 RNA expression was used as previously described. 4 In CMPD and CMML cases, significantly reduced H19 RNA levels were found compared to normal bone marrow cells. Both prefibrotic and fibrotic IMF exhibited a three-fold lower level, PV, ET, and CML exhibited a six-fold lower level, and CMML cases exhibited a 20-fold lower level compared to normal bone marrow cells. To illustrate the different expression levels, the basal expression level of the control group was set to 1. 
